Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
04 nov. 2020 08h30 HE
|
Prothena Corporation plc
Next generation anti-Aβ antibodies being developed for subcutaneous administration to improve access for patients with Alzheimer’s diseaseMulti-immunogen Aβ-tau vaccine being developed for the...
Prothena to Report Third Quarter 2020 Financial Results on November 4
28 oct. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of...
Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
20 oct. 2020 16h05 HE
|
Prothena Corporation plc
First anti-alpha-synuclein antibody to advance into confirmatory large study in patients with early Parkinson’s disease; expected to initiate in 2021Prothena to earn a $60 million clinical milestone...
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 oct. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
15 sept. 2020 08h30 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
11 sept. 2020 08h30 HE
|
Prothena Corporation plc
First potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints, including measures of...
Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
08 sept. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
03 sept. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 sept. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
06 août 2020 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarter-end cash and restricted cash position of $336.6...